Hiroaki Kikukawa

771 total citations
21 papers, 210 citations indexed

About

Hiroaki Kikukawa is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Hiroaki Kikukawa has authored 21 papers receiving a total of 210 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Hiroaki Kikukawa's work include Prostate Cancer Treatment and Research (7 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Bone health and treatments (5 papers). Hiroaki Kikukawa is often cited by papers focused on Prostate Cancer Treatment and Research (7 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Bone health and treatments (5 papers). Hiroaki Kikukawa collaborates with scholars based in Japan, United States and Sweden. Hiroaki Kikukawa's co-authors include Shoichi Ueda, Masaki Yoshida, Makoto Yono, Akito Inadome, Hiroshi Seshita, Wataru Takahashi, Wataru Takahashi, Yoshihiro Wada, Yuki Wada and Kenichi Kitani and has published in prestigious journals such as Journal of Clinical Oncology, Life Sciences and European Journal of Pharmacology.

In The Last Decade

Hiroaki Kikukawa

20 papers receiving 204 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hiroaki Kikukawa Japan	9	82	55	46	38	36	21	210
Po‐Fan Hsieh Taiwan	10	47 0.6×	159 2.9×	29 0.6×	31 0.8×	66 1.8×	39	312
José A. Lorente Spain	8	26 0.3×	110 2.0×	41 0.9×	8 0.2×	24 0.7×	15	367
Elena Morini Italy	11	56 0.7×	96 1.7×	10 0.2×	6 0.2×	19 0.5×	24	286
P. A. Gammelgaard Denmark	9	50 0.6×	155 2.8×	32 0.7×	12 0.3×	30 0.8×	21	268
R Hampel Germany	9	36 0.4×	15 0.3×	65 1.4×	12 0.3×	39 1.1×	21	257
C. Florio Italy	9	8 0.1×	10 0.2×	25 0.5×	8 0.2×	70 1.9×	10	255
Ravi S. Shah United States	11	8 0.1×	28 0.5×	117 2.5×	8 0.2×	14 0.4×	39	263
Malene Hornbak Denmark	7	18 0.2×	17 0.3×	40 0.9×	2 0.1×	14 0.4×	11	119
Francesco Moretto Italy	12	6 0.1×	141 2.6×	28 0.6×	89 2.3×	4 0.1×	19	315
Kui Li China	10	5 0.1×	10 0.2×	21 0.5×	41 1.1×	21 0.6×	29	262

Countries citing papers authored by Hiroaki Kikukawa

Since Specialization

Citations

This map shows the geographic impact of Hiroaki Kikukawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroaki Kikukawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroaki Kikukawa more than expected).

Fields of papers citing papers by Hiroaki Kikukawa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroaki Kikukawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroaki Kikukawa. The network helps show where Hiroaki Kikukawa may publish in the future.

Co-authorship network of co-authors of Hiroaki Kikukawa

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroaki Kikukawa. A scholar is included among the top collaborators of Hiroaki Kikukawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroaki Kikukawa. Hiroaki Kikukawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Powles, Thomas, Michiel Simon Van Der Heijden, Ying Wang, et al.. (2025). Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA.. Journal of Clinical Oncology. 43(16_suppl). 4503–4503. 6 indexed citations

Matsubara, Nobuaki, Hiroji Uemura, Atsushi Mizokami, et al.. (2024). Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First‐Line Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: TALAPRO ‐2 Japanese Subgroup Analysis. Cancer Medicine. 14(1). e70333–e70333.

Kohno, Shigeru, Hiroyuki Bando, Hiroaki Kikukawa, et al.. (2020). The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study. Journal of Infection and Chemotherapy. 27(2). 262–270. 18 indexed citations

Okuno, Nozomi, Gaku Arai, Hiroomi Nakatsu, et al.. (2020). Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study. Japanese Journal of Clinical Oncology. 51(4). 544–551. 3 indexed citations

Uemura, Hirotsugu, Hiroji Uemura, Yoshiaki Wakumoto, et al.. (2019). Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases. International Journal of Clinical Oncology. 24(5). 557–566. 11 indexed citations

Matsubara, Nobuaki, Go Kimura, Hiroji Uemura, et al.. (2019). A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study. International Journal of Clinical Oncology. 25(4). 720–731. 8 indexed citations

Matsubara, Nobuaki, Yoshiaki Wakumoto, Hirotsugu Uemura, et al.. (2017). Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer. International Journal of Clinical Oncology. 23(1). 173–180. 19 indexed citations

Uemura, Hiroji, Satoshi Nagamori, Yoshiaki Wakumoto, et al.. (2016). Phase II clinical study of radium-223 chloride (BAY 88-8223) in Japanese patients with symptomatic castration-resistant prostate cancer (CRPC) with bone metastases.. Journal of Clinical Oncology. 34(2_suppl). 167–167. 1 indexed citations

Wada, Yoshihiro, Ken Kikuchi, Wataru Takahashi, et al.. (2007). Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer. Cancer Chemotherapy and Pharmacology. 61(1). 53–61. 4 indexed citations

10.

Wada, Yoshihiro, Tomohiro Kuwahara, Eiichiro Uyama, et al.. (2006). Neurologic toxicity associated with interferon α therapy for renal cell carcinoma. International Journal of Urology. 13(6). 811–813. 4 indexed citations

11.

Wada, Yoshihiro, Yukio Ando, Nobuyuki Kai, et al.. (2006). Lower urinary tract dysfunction in type 1 familial amyloidotic polyneuropathy in Kumamoto, Japan. International Journal of Urology. 13(12). 1475–1478. 5 indexed citations

12.

Wada, Yoshihiro, Yutaka Sugiyama, Hiroaki Kikukawa, et al.. (2004). Isolated Renal Tuberculosis following Intravesical Bacillus Calmette-Guérin Therapy for Bladder Cancer. Urologia Internationalis. 72(3). 257–260. 10 indexed citations

13.

Kuwahara, Tomohiro, Yoshihiro Wada, Wataru Takahashi, et al.. (2003). Effects of Diabetes on Nitric Oxide-Mediated Relaxations in Male Rat Corpus cavernosum Smooth Muscle. Urologia Internationalis. 71(4). 399–407. 2 indexed citations

14.

Wada, Yuki, et al.. (2003). Primitive neuroectodermal tumour of the kidney with spontaneous regression of pulmonary metastases after nephrectomy. British Journal of Urology. 91(1). 121–122. 9 indexed citations

15.

Tokunaga, Jin, Hiroaki Kikukawa, Junko Fujii, et al.. (2000). [Pharmacokinetics of cisplatin and methotrexate in a patient suffering from advanced ureteral tumor accompanied by chronic renal failure, undergoing combined hemodialysis and systemic M-VAC chemotherapy].. PubMed. 27(13). 2079–85. 10 indexed citations

16.

Yono, Makoto, Masaki Yoshida, Hiroaki Kikukawa, et al.. (1999). Pharmacological effects of tolterodine on human isolated urinary bladder. European Journal of Pharmacology. 368(2-3). 223–230. 42 indexed citations

17.

Inadome, Akito, Masaki Yoshida, Wataru Takahashi, et al.. (1998). Measurement of acetylcholine released from rabbit detrusor smooth muscle using HPLC with electro-chemical detection coupled with microdialysis procedure. Life Sciences. 62(26). PL393–PL399. 10 indexed citations

18.

Kikukawa, Hiroaki, et al.. (1998). Pharmacologic Actions of Temiverine (p‐l NN) and its Active Metabolite, RCC‐36, on Isolated Human Urinary Bladder Muscle. International Journal of Urology. 5(3). 268–275. 8 indexed citations

19.

Wada, Yuki, Masaki Yoshida, Kenichi Kitani, et al.. (1996). Comparison of the effects of various anticholinergic drugs on human isolated urinary bladder.. PubMed. 330(1). 76–89. 37 indexed citations

20.

Kikukawa, Hiroaki, et al.. (1992). URINARY DISTURBANCE DUE TO HTLV-1 ASSOCIATED MYELOPATHY. The Japanese Journal of Urology. 83(12). 2058–2061. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact